J&J: positive results for tremfya in psoriasis

(CercleFinance.com) - Johnson & Johnson's Janssen Pharmaceutical Companies today announced that new data has showed that initiation of Tremfya (guselkumab) in patients with moderate-to-severe plaque psoriasis (PsO) resulted in greater treatment persistence compared to secukinumab or ixekizumab.


In addition, a post-hoc analysis of the results of a phase III trial shows that Tremfya demonstrated a sustained clinical efficacy, relief of itching and improvements in quality of life in patients with PsO of the scalp.

These results potentially indicate that Tremfya is associated with better long-term control of PsO-associated symptoms compared to secukinumab and ixekizumab, regardless of whether patients are biologically naive or biologically experienced, a related source noted.


Copyright (c) 2023 CercleFinance.com. All rights reserved.